Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.31 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | CA7 | P43166 | 3/20 | 0.31 |
| ▸ | CA9 | Q16790 | 3/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27685064 | 0.84 | GAA (0.35) | TUBB1MRGPRX4GAAMGAMSI | |
| SCHEMBL3599329 | 0.80 | MGAM (0.39) | TUBB1MRGPRX4GAAMGAMSI | |
| SCHEMBL27658885 | 0.80 | TUBB1 (0.33) | TUBB1MRGPRX4GAAMGAMSI | |
| SCHEMBL27610584 | 0.80 | ADRA2A (0.35) | TUBB1GAAKDM4EMAPTMAPK1 | |
| SCHEMBL31063050 | 0.79 | CA1 (0.43) | TUBB1MRGPRX4GAAMGAMSI | |
| SCHEMBL8244029 | 0.79 | CA1 (0.43) | TUBB1MRGPRX4GAAMGAMSI | |
| SCHEMBL15682035 | 0.78 | CA2 (0.47) | TUBB1MRGPRX4CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL27666698 | 0.76 | IDO1 (0.38) | TUBB1GAAKDM4EMAPTNFE2L2 | |
| SCHEMBL27475051 | 0.74 | MEP1B (0.34) | — | |
| SCHEMBL27536491 | 0.73 | ALDH1A1 (0.33) | TUBB1MRGPRX4CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2805954-B1 | 7-SUBSTITUTED HANFANGICHIN B DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | HANGZHOU BENSHENG PHARMACEUTICAL CO LTD (CN) | 2019-06-19 | — | — | EP | disclosed |
| US-9328122-B2 | 7-substituted Hanfangichin B derivative, and preparation method and use thereof | HANGZHOU BENSHENG PHARMACEUTICALS CO., LTD. (CN) | 2016-05-03 | — | — | US | disclosed |
| CN-102781884-B | Process for producing alpha-olefin oligomer | MITSUBISHI CHEMICAL CORP. (JP) | 2015-11-25 | — | — | CN | disclosed |
| CN-104955332-A | Method for controlling arthropod pest | SUMITOMO CHEMICAL CO | 2015-09-30 | — | — | CN | disclosed |
| CN-104926589-A | Process for producing alpha-olefin oligomer | MITSUBISHI CHEM CORP | 2015-09-23 | — | — | CN | disclosed |
| CN-102869661-B | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2015-08-05 | — | — | CN | disclosed |
| US-20140357647-A1 | 7-SUBSTITUTED HANFANGICHIN B DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | HANGZHOU BENSHENG PHARMACEUTICAL CO., LTD. (CN) | 2014-12-04 | — | — | US | disclosed |
| CN-102112479-B | Buprenorphine analogs | PURDUE PHARMA L.P. (US) | 2014-10-29 | — | — | CN | disclosed |
| CN-101801949-B | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA NV | 2014-09-24 | — | — | CN | disclosed |
| CN-103450206-A | Buprenorphine analogs | PURDUE PHARMA LP | 2013-12-18 | — | — | CN | disclosed |
| CN-1294577-A | Potassium channel inhibitors | ICAGEN INC (US) | 2001-05-09 | — | — | CN | disclosed |
| WO-2000010565-A1 | GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 2000-03-02 | — | — | WO | disclosed |
| CN-1046722-C | Heterocyclic compounds and their preparation and use | NOVO NORDISK AS (DK) | 1999-11-24 | — | — | CN | disclosed |
| EP-0933365-A2 | Growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0898963-A2 | Congestive heart failure treatment | ELI LILLY AND COMPANY (US) | 1999-03-03 | — | — | EP | disclosed |
| WO-1999008699-A1 | GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 1999-02-25 | — | — | WO | disclosed |
| WO-1999008697-A1 | TREATMENT OF CONGESTIVE HEART FAILURE WITH GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 1999-02-25 | — | — | WO | disclosed |
| CN-1202152-A | Novel 4- (oxoxyphenyl) -3-oxopiperidines for the treatment of cardiac and renal insufficiency | HOFFMANN LA ROCHE (CH) | 1998-12-16 | — | — | CN | disclosed |
| CN-1040979-C | Antipsychotic method | NOVO NORDISK AS (DK) | 1998-12-02 | — | — | CN | disclosed |
| CN-1121349-A | Heterocyclic compounds and their preparation and use | NOVO NORDISK AS (DK) | 1996-04-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357647-A1 | 7-SUBSTITUTED HANFANGICHIN B DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | UGT2B7, CYP3A7, UGT1A7 | TUBB1 1449/4885MRGPRX4 624/4885GAA 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.